Biodegradable Drug Depots for Localized Alpha-2 Agonist Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain and inflammation associated with conditions like tendonitis, carpal tunnel syndrome, and osteoarthritis often rely on systemic opioids, which come with significant side effects, and alpha adrenergic receptor agonists have not been widely recognized as effective for these conditions.
Innovation Solution
Development of implantable biodegradable drug depots containing alpha adrenergic agonists, specifically alpha-2 adrenergic agonists like clonidine, that can be administered locally beneath the skin or gum to provide sustained release of the medication, reducing pain and inflammation over extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic opioids are used to treat pain and inflammation, then effective pain control is achieved, but significant side effects occur including respiratory depression, sedation, and constipation
Solution Approach 1:
The invention divides the drug delivery system into localized implantable depots placed at specific injury sites, separating the therapeutic action from systemic circulation. This segmentation allows pain control at the target site while avoiding widespread distribution that causes side effects
Solution Approach 2:
The patent applies local quality by concentrating the opioid medication specifically at the injury site through implantable depots. The high concentration is localized precisely where needed, while the surrounding tissues and systemic circulation receive minimal exposure, thereby achieving effective pain control without the harmful systemic effects
2Duration of action of moving object
If opioids are administered systemically for extended periods, then sustained pain relief is achieved, but patient recovery and mobility are hindered by disabling side effects
Solution Approach 1:
The implantable depot system segments the duration of action into controlled release phases at the local site. The sustained release occurs locally over time without requiring repeated systemic administration, thereby maintaining pain relief while avoiding the cumulative disabling effects of prolonged systemic opioid use
Solution Approach 2:
The invention performs preliminary action by implanting the drug depot before the full course of treatment is needed. The depot is预先 placed and begins controlled release, providing sustained pain relief from the outset without requiring multiple systemic doses that would progressively impair recovery and mobility
3Object-affected harmful factors
If alpha adrenergic receptor agonists are used for pain and inflammation, then localized pain control can be achieved, but the therapeutic effectiveness has not been widely recognized or established
Solution Approach 1:
The invention applies parameter changes by using alpha adrenergic receptor agonists at specific concentrations and delivery rates through the implantable depot system. This controlled parameter approach allows the drug to achieve therapeutic effectiveness for pain and inflammation while maintaining the advantage of fewer side effects compared to traditional opioid therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biodegradable drug depots effectively reduce and prevent pain and inflammation for conditions such as tendonitis, carpal tunnel syndrome, and osteoarthritis by providing localized, sustained delivery of alpha adrenergic agonists, minimizing systemic side effects and improving treatment duration.
Implementation Method 1
the drug depot being capable of releasing an effective amount of the alpha adrenergic agonist over a period of at least one day
Implementation Method 2
implantable biodegradable drug depots
Data Source
AI summary
Effective treatments of pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease.